"synopsis" may belong to another edition of this title.
Shipping:
£ 3.23
Within U.S.A.
Book Description Condition: New. Seller Inventory # ABLIING23Mar3113020276182
Book Description Condition: New. PRINT ON DEMAND Book; New; Fast Shipping from the UK. No. book. Seller Inventory # ria9783659294808_lsuk
Book Description PF. Condition: New. Seller Inventory # 6666-IUK-9783659294808
Book Description Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Recent reports have demonstrated that topical ocular administration of naltrexone (an opioid growth factor antagonist) is able to reverse the diabetic complications on the cornea (diabetic keratopathy). The topical administration of naltrexone accelerates corneal wound healing, restores corneal sensitivity and enhances corneal epithelialisation in diabetic rats, rabbits and humans. Naltrexone can be considered as a new therapeutic agent for treatment of diabetic keratopathy. To our best knowledge, an ophthalmic formulation has not yet been developed for naltrexone hydrochloride (NTX) nor has it been properly formulated in a liquid dosage form. This book is designed of six chapters. The first chapter includes a general introduction to the major constraints for topical ocular drug delivery, and a review on new therapeutic approaches in treatment of diabetic keratopathy. The second chapter is preformulation studies of NTX and followed by two formulation chapters for niosomes (non-ionic surfactant vesicles). Chapter five deals with evaluation of niosomes for ocular delivery of NTX and finally chapter six presents a general discussion and direction for future research. 332 pp. Englisch. Seller Inventory # 9783659294808
Book Description PAP. Condition: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Seller Inventory # L0-9783659294808
Book Description PAP. Condition: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Seller Inventory # L0-9783659294808
Book Description Taschenbuch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Recent reports have demonstrated that topical ocular administration of naltrexone (an opioid growth factor antagonist) is able to reverse the diabetic complications on the cornea (diabetic keratopathy). The topical administration of naltrexone accelerates corneal wound healing, restores corneal sensitivity and enhances corneal epithelialisation in diabetic rats, rabbits and humans. Naltrexone can be considered as a new therapeutic agent for treatment of diabetic keratopathy. To our best knowledge, an ophthalmic formulation has not yet been developed for naltrexone hydrochloride (NTX) nor has it been properly formulated in a liquid dosage form. This book is designed of six chapters. The first chapter includes a general introduction to the major constraints for topical ocular drug delivery, and a review on new therapeutic approaches in treatment of diabetic keratopathy. The second chapter is preformulation studies of NTX and followed by two formulation chapters for niosomes (non-ionic surfactant vesicles). Chapter five deals with evaluation of niosomes for ocular delivery of NTX and finally chapter six presents a general discussion and direction for future research. Seller Inventory # 9783659294808
Book Description Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Abdelkader HamdyDr Hamdy Abdelkader received his BPharm from Alexandria University, Egypt in 2000 and he has been a registered pharmacist since 2001. Hamdy received his PhD in Pharmaceutics from The University of Auckland, New Zealan. Seller Inventory # 5146409